Skip to main content
Equibles
SNDX logo

SNDX · Syndax Pharmaceuticals Inc · Earnings Call Transcripts & Audio

Track SNDX — free

Use SNDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SNDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.80 +0.57 (+3.10%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$1.63B
Shares
89.30M
Volume · Sep 30 1.73M Avg daily vol (3M) 1.61M

Syndax Pharmaceuticals Inc Earnings Call Transcripts

Quarterly earnings calls for Syndax Pharmaceuticals Inc (SNDX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$44.62M '23 Q2 23-08-03 · $ −$51.15M '23 Q3 23-11-02 · $ −$72.40M '24 Q1 24-05-08 · $3.50M −$68.06M '24 Q2 24-08-01 · $12.50M −$84.13M '24 Q3 24-11-05 · $7.68M −$94.17M '24 Q4 25-03-03 · $20.04M −$84.85M '25 Q1 25-05-05 ▲984.5% $37.96M −$71.85M '25 Q2 25-08-04 ▲267% $45.87M −$60.72M '25 Q3 25-11-03 ▲791.7% $68.48M −$68.01M '25 Q4 26-02-26 ▲223.6% $64.86M −$42.67M '26 Q1 26-04-30 LATEST ▲91.8% $72.79M −$49.36M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Syndax Pharmaceuticals Inc (SNDX) Q2 2026 Earnings Call Transcript
Positive tone RevuForge (menin inhibitor) commercial performance Upcoming clinical data catalysts Pipeline assets / new clinical programs
Revenue
$72.79M
▲ 91.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call
Revenue
$64.86M
▲ 223.6% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Transcript
Confident tone Revuforj (revumenib) commercial launch and growth NPM1 mutated AML indication expansion Niktimvo (axatilimab) in chronic GVHD
Revenue
$68.48M*
▲ 791.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Transcript
Confident tone Revuforj commercial launch and demand momentum NPM1 label expansion and NCCN guideline inclusion KMT2A penetration and post-transplant maintenance
Revenue
$45.87M
▲ 267% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Syndax Pharmaceuticals Inc (SNDX) Q2 2025 Earnings Call Transcript
Confident tone Revuforj (revumenib) commercial launch Niktimvo (chronic GVHD) launch Menin inhibitor pipeline / frontline opportunity
Revenue
$37.96M
▲ 984.5% YoY
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Transcript
Confident tone Niktimvo commercial launch Revuforj commercial launch Menin inhibitor first-mover leadership
Revenue
$20.04M
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Transcript
Confident tone Revuforj launch and commercial uptake Combination trials and clinical development pipeline Niktimvo launch in chronic GVHD
Revenue
$7.68M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Transcript
Confident tone Revumenib regulatory progress Clinical data and ASH presentations Frontline combination strategy
Revenue
$12.50M
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Transcript
Confident tone Axatilimab launch in chronic GVHD Revumenib FDA approval and PDUFA delay Combination data presentations at EHA
Revenue
$3.50M
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript
Confident tone revumenib regulatory and clinical progress Commercial launch preparation axatilimab regulatory progress
Revenue
$
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Syndax Pharmaceuticals Inc (SNDX) Q4 2023 Earnings Call Transcript
Confident tone Revumenib (menin inhibitor) pivotal data and NDA Axatilimab in chronic GVHD approval Combination strategies for revumenib
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Syndax Pharmaceuticals Inc (SNDX) Q2 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Syndax Pharmaceuticals Inc (SNDX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Syndax Pharmaceuticals Inc (SNDX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Syndax Pharmaceuticals Inc (SNDX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Syndax Pharmaceuticals Inc (SNDX) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Syndax Pharmaceuticals Inc (SNDX) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Syndax Pharmaceuticals Inc (SNDX) Q4 2021 Earnings Call Transcript
Revenue
$126.58M*
▲ 33209.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Syndax Pharmaceuticals Inc (SNDX) Q3 2021 Earnings Call Transcript
Revenue
$12.38M
▲ 3165.2% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Syndax Pharmaceuticals Inc (SNDX) Q2 2021 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Diluted EPS
$-0.44
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Syndax Pharmaceuticals Inc (SNDX) Q1 2021 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Syndax Pharmaceuticals Inc (SNDX) Q4 2020 Earnings Call Transcript
Revenue
$380,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Syndax Pharmaceuticals Inc (SNDX) Q3 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Syndax Pharmaceuticals Inc (SNDX) Q2 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Syndax Pharmaceuticals Inc (SNDX) Q1 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Syndax Pharmaceuticals Inc (SNDX) Q4 2019 Earnings Call
Revenue
$380,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1395937 CUSIP 87164F105 13F (30d) 7 filings 7 filers Visit website Investor relations